An international expert in the financing and growth of high tech businesses
Paris, France – May 3rd – LinKinVax, a clinical-stage biotechnology company specializing in the treatment of infectious diseases and certain forms of cancer, announces the appointment of Dr. Jiong Ma as independent board member.
“As we enter the clinical stages of a number of drug candidates (HPV, Covid) resulting from our innovative vaccine platform, I am delighted to welcome Dr. Jiong Ma as an addition to our board. With a longstanding focus on the financing and growth of high tech businesses, her role will be to support us in our platform development strategy and to help us achieve our ambitions on a global scale. Dr. Jiong Ma benefits from in-depth experience of very high value-added innovative industries and will provide her extensive knowledge of international markets, in particular the North American and Asian markets, as well as her investment and business development network,” comments André-Jacques Auberton-Hervé, Chairman and Co-Founder of LinKinVax.
“It is an honor to be joining the LinKinVax board,” states Dr. Jiong Ma. “By putting the emphasis on infectious diseases and certain forms of cancer, LinKinVax uses its innovative technology to tackle the biggest health issues facing our society today and in decades to come. I am impressed by the extent of LinKinVax’s pipeline and the advances it has made. I cannot wait to put forward my ideas to help the Company achieve the next stages in its growth.”
Dr. Jiong Ma brings over 25 years of experience in investing, building, and scaling technology companies. Based in the United States, she served as Senior Partner and a member of the investment committee at Braemar Energy Ventures, leading investments in resource efficiency, e-mobility, industrial digitalization, renewable energy, and deep tech.
She is founder and board of director of Chavant Capital Acquisition Corp. (Nasdaq: CLAY). Ms. Ma serves on the boards Solid Energy Systems (NYSE: SES), Anavex Life Sciences Corporation (Nasdaq: AVXL). In addition, she is an advisory board member for National Renewable Energy Labs.
Previously, Jiong was an investment professional at 3i, a global private equity firm, where she led investments in technology and media, digital health and cleantech. Jiong held several senior positions at Lucent Technologies and Bell Labs, responsible for product portfolio strategy, new product launches, and research and product development.
Dr. Ma holds a PhD in Electrical and Computer Engineering from the University of Colorado at Boulder, an MS in Electrical Engineering from Worchester Polytechnic Institute, and a BS in Physics and Electrical Engineering from Lanzhou University in China. She is also a Kauffman Fellow.
Thanks to the potential of its technology platform and the advances in its portfolio, LinKinVax aims to make a decisive contribution to the global public health challenges of infectious diseases and cancer.
Contact LinKinVax :
Corinne Margot – email@example.com
Press Contact LinKinVax :
Annie-Florence Loyer – firstname.lastname@example.org – +33(0) 6 88 20 35 59
About LinKinVax technology
LinKinVax’s vaccine platform is built around a humanized monoclonal antibody, which is merged with regions of pathogens of interest, targeting the CD40 molecule expressed by dendritic cells, DC, which play a key role in stimulating the immune system. The results obtained demonstrate the benefits of this strategy owing to the small quantity of antigens required to activate the immune system, with or without an adjuvant, and its ability to trigger a lasting cellular and humoral and immune response. The platform also benefits from the experience and safety profile of the protein-based vaccines that have been widely used for over 30 years now.
Three products are in or about to enter clinical trials: a prophylactic vaccine for HIV, currently in phase I led by Inserm/ANRS-EID), a SARS-CoV-2 vaccine covering variants of interest, and a therapeutic vaccine for human papillomavirus-related cancers.
LinKinVax was founded in 2020 and is led by two internationally renowned personalities in the worlds of medicine, industry and business, namelyAndré-Jacques Auberton-Hervé, Honorary Chairman and founder of SOITEC, and Prof. Yves Levy, MD, PhD, immunologist, and Director of the Vaccine Research Institute (VRI/INSERM/UPEC). LinKinVax is developing an innovative protein-based vaccine platform that can accelerate availability of vaccines by leveraging the research conducted at the Vaccine Research Institute (VRI). This DC Targeting-based protein vaccine platform can adapt to changes and mutations in the target pathogens. For further information, please visit www.linkinvax.com